ASH 2018 | Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia vera
The 5-year efficacy and safety date from the Phase III RESPONSE study (NCT01243944) are discussed here by Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France. This study compared ruxolitinib with the best available therapy in hydroxyurea-resistant/intolerant polycythemia vera patients. This analysis, presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, consolidated the long-term clinical benefits of ruxolitinib.
Get great new content delivered to your inboxSign up